Our approach for analyzing arterial and endothelial function data provides a unique means for diagnosis and monitoring at the point of care.
New Brunswick, NJ (PRWEB) November 28, 2012
Rutgers announced today that it has agreed to an exclusive license with Everist Genomics Inc. for the patents covering a novel technology that enables the early measurement of various vascular conditions. Gary M. Drzewiecki, professor in the university’s Department of Biomedical Engineering, developed the technology.
“The accuracy and clinical relevance of the available non-invasive measurement techniques has been a challenge until now,” Drzewiecki said. “Our approach for analyzing arterial and endothelial function data provides a unique means for diagnosis and monitoring at the point of care.”
Everist Genomics intends to develop and commercialize products based on the Rutgers’ patents utilizing its AngioDefender device platform. The system uses non-invasive sensor technology and a sophisticated software algorithm to rapidly provide physicians with data that helps them detect early stage cardiovascular disease such as atherosclerosis.
Stuart Palmer, director of life science licensing for Rutgers, said “We are very pleased and excited to be able to partner with a company with the capabilities of Everist Genomics and to see the translation of our basic research into the clinic in the form of the AngioDefender system.”
“This is an example of great university research combining with private business to create a breakthrough product that can improve health care throughout the world,” said Alex Charlton, executive vice chairman of Everist Genomics, headquartered in Ann Arbor, Mich. “This low-cost test, using Rutgers technology, is already gaining acceptance in the Indian market where we have partnered with the Manipal Group, a major health care provider. We are also installing AngioDefenders in the Middle East and have regulatory approval to introduce the product to 27 European countries. We believe the AngioDefender will be rapidly established as the most accurate and cost-effective test for assessing the cardiovascular health of patients, particularly those without obvious symptoms.”
About Rutgers, The State University of New Jersey: Rutgers is one of the nation’s leading comprehensive public research universities and New Jersey’s only public university in New Jersey in the Association of American Universities. The AAU is a prominent group of 62 leading research universities recognized for the quality and scope of their research and educational programs. Research expenditures at Rutgers grew to $473.1 million in FY2011, including a federal-funding increase of nearly 8% over FY2010. With three campuses, Rutgers has more than 200 research institutes/centers, 58,000 students, and 13,000 faculty and staff.
About Rutgers Office of Technology Commercialization: Rutgers Office of Technology Commercialization turns academic discoveries into commercial successes. To do so, the office provides patenting, marketing, licensing, start-up company formation, and other commercialization support to students and faculty researchers on all three of the university’s campuses. More than 80 start-up companies have been created based on Rutgers technologies; two thirds of these are New Jersey-based.
About Everist Genomics, Inc.: Everist Genomics, Inc. (EGI) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies which help physicians improve medical outcomes and reduce the total cost of care. EGI's innovative products successfully integrate with mobile digital services, smart phones, and tablet computers resulting in advanced medical technology which until now has been confined to the hospital setting. Everist Genomics is an Ann Arbor, Mich.,-based company that has been developed with support from the Michigan Economic Development Corporation (MEDC).
About the AngioDefender System: AngioDefender is the world’s first non-invasive device that successfully combines patent protected non-invasive sensor technology and a sophisticated software algorithm to quickly and cost effectively assesses Endothelial Cell Dysfunction (‘EDF’) and flow mediated dilation (‘FMD’) of the Brachial Artery (‘BA’). The entire AngioDefender procedure is completed in less than 15 minutes and the system transmits 25 components of information, including relevant elements of the patient record and CVD diagnostic data to a desk-top computer, laptop, notebook or tablet. For additional information, please see http://www.everistgenomics.com/content/angiodefender/angiodefender.htm
For further information on technology commercialization at Rutgers, visit http://otc.rutgers.edu/. For further information on partnership opportunities with the AngioDefender, contact: Vicki Theisen, General Manager, Everist Genomics, Inc., vt(at)everistgenomics(dot)com.
# # #